ERBB2 and inflammatory breast carcinoma: Genomic studies have highlighted common mutations in IBC, such as MYC (32%), PIK3CA (28%), HER2 (26%), and FGFR1 (17%) amplifications and TP53 (62%), BRCA2 (15%), and PTEN (15%) mutations [12].